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ABSTRACT

ARTICLE HISTORY

The objective of the present review is to synthesize the information on the cellular and molecular
players responsible for maintaining a homeostatic balance between a naturally invasive human
placenta and the maternal uterus in pregnancy; to review the roles of decorin (DCN) as a molecular
player in this homeostasis; to list the common maladies associated with a break-down in this
homeostasis, resulting from a hypo-invasive or hyper-invasive placenta, and their underlying
mechanisms. We show that both the fetal components of the placenta, represented primarily by the
extravillous trophoblast, and the maternal component represented primarily by the decidual tissue
and the endometrial arterioles, participate actively in this balance. We discuss the process of uterine
angiogenesis in the context of uterine arterial changes during normal pregnancy and preeclampsia.
We compare and contrast trophoblast growth and invasion with the processes involved in
tumorigenesis with special emphasis on the roles of DCN and raise important questions that remain
to be addressed. Decorin (DCN) is a small leucine-rich proteoglycan produced by stromal cells,
including dermal ﬁbroblasts, chondrocytes, chorionic villus mesenchymal cells and decidual cells of
the pregnant endometrium. It contains a 40 kDa protein core having 10 leucine-rich repeats
covalently linked with a glycosaminoglycan chain. Biological functions of DCN include: collagen
assembly, myogenesis, tissue repair and regulation of cell adhesion and migration by binding to
ECM molecules or antagonising multiple tyrosine kinase receptors (TKR) including EGFR, IGF-IR,
HGFR and VEGFR-2. DCN restrains angiogenesis by binding to thrombospondin-1, TGFb, VEGFR-2
and possibly IGF-IR. DCN can halt tumor growth by antagonising oncogenic TKRs and restraining
angiogenesis. DCN actions at the fetal-maternal interface include restraint of trophoblast migration,
invasion and uterine angiogenesis. We demonstrate that DCN overexpression in the decidua is
associated with preeclampsia (PE); this may have a causal role in PE by compromising endovascular
differentiation of the trophoblast and uterine angiogenesis, resulting in poor arterial remodeling.
Elevated DCN level in the maternal blood is suggested as a potential biomarker in PE.
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Structure of the human placenta as an invasive
organ
The human placenta is a highly invasive organ in which a
subpopulation of trophoblast cells proliferate, migrate
and invade the uterine endometrium and its arteries to
nourish the fetus.1,2 Adequate placental perfusion with
maternal blood depends on highly regulated invasion
and remodeling of utero-placental arteries by the trophoblast.3,4 There are 2 distinct pathways of trophoblast differentiation from the bipotent stem cells in the
cytotrophoblast layer of chorionic villi (Fig. 1): the villous
pathway, in which cells proliferate and fuse, giving rise to
the syncytiotrophoblast layer facing the maternal sinusoids, engaged primarily in exchange and endocrine
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functions; and the extravillous pathway in which cells
break out of the villi as discrete cell columns which proliferate at their base,5,6 migrate and invade the decidua
and its arteries by adopting an “endovascular phenotype”
(expressing certain endothelial cell markers) and replace
the endothelial lining of the arteries.7-9 Proliferation,
migration and invasiveness of the extravillous trophoblast (EVT) cells are exquisitely regulated in situ,1,2,10
and this may fail in certain pathological conditions. Poor
EVT invasion and arterial remodeling underlies preeclampsia and certain forms of intrauterine growth
restriction (IUGR),4,11-13 whereas uncontrolled invasion
features trophoblastic neoplasias, including invasive
moles and choriocarcinomas.13
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Figure 1. Schematic diagram of human placenta at approximately 10 weeks of gestation showing the fetal compartment
including the trophoblast and maternal sinusoids, and the maternal compartment including the decidua and uterine vessels (UV).
Chorionic villi (CV) consist of 2 layers of trophoblast cells, the
inner cytotrophoblast (CT) and the outer syncytiotrophoblast
(ST). Cytotrophoblast cells in some villi known as anchoring villi
(AV) migrate out as cell columns as extravillous trophoblasts
(EVT) to invade the decidua. Some EVT cells remain dispersed in
the deciduas as interstitial trophoblast (IT), some fuse to become
trophoblast giant cells (GC) and others form cytotrophoblastic
shell (CS) bordering the decidua and the maternal sinusoids.
Some EVT cells from the CS enter uterine arteries as endovascular
trophoblasts. It is also suggested that some IT cells invade the
arteries from the exterior. (Reproduced with permission from Graham CH and Lala PK. Biochem Cell Biology 1992; 70: 867–874.).

Uterine angiogenesis and arterial remodeling
during normal pregnancy and preeclampsia
While blood vessels in the fetal compartment of the
placenta arise by the process of “vasculogenesis” by
recruitment of mesenchymally derived angioblasts,
those in the maternal compartment represented by the
decidualized endometrium arise by sprouting from
pre-existing uterine vessels, or the process of “angiogenesis.” The arteries, but not the veins, in the endometrium and the inner third of the myometrium are
extensively modiﬁed during normal pregnancy by the
EVT cells. It has been suggested that EVT cell preference for migration toward the uterine arteries rather
than veins is guided by the differential expression of
chemokine receptors ephrin type-B receptor 2
(EPHB2) on arterial endothelium and ephrin type-B
receptor 4 (EPHB4) on venous endothelium and their
transmembrane ligand ephrin on EVT cells.14 The
modiﬁcation or “remodeling” of the arteries is a process characterized by the disruption, and eventual loss
of the smooth muscle cells, described as “ﬁbrinoid

necrosis” of the tunica media,15,16 loss of elastic ﬁbers
and replacement of the endothelial lining with EVT
cells which have adopted an “endovascular phenotype.”3,4,15 Endovascular phenotype or “endovascular
differentiation” of the trophoblast is characterized by
gestational age-dependent acquisition of endothelial
markers VE-cadherin, VCAM-1, PECAM-1 and Ncadherin.15,17 Prior to the arrival of EVT cells, the
uterine arteries, possibly primed by pregnancy-associated hormones, undergo certain morphological and
molecular changes in the endothelium such as basophilia, swelling and expression of the endothelial activation marker VCAM. This is regarded as the
trophoblast-independent phase of arterial remodeling,18 while subsequent completion of the remodeling
process is considered as trophoblast-dependent.15
There are 2 views on EVT cell entry, presumably leading to the disruption of vascular smooth muscle cells
(VSMC): (i) Certain EVT cells in the cytotrophoblastic
shell (Fig. 1) undergo endovascular differentiation and
invade the distal ends of the arterioles within the
endometrium to cause apoptosis of the endothelial
cells; they crawl against the blood-ﬂow to replace the
endothelial lining as far as the distal third of the myometrium. (ii) Interstitial EVT cells located deeper in
the decidua invade the arteries from outside.19,20
While these 2 views are not mutually exclusive, presence of interstitial EVT cells has not been documented
within the myometrium. In vitro studies suggest that
EVT cells when confronting myometrial smooth muscle cells produce Mel-CAM (also known as MUC18
and CD146), an anti-migratory molecule.21 Another
feature of the arterial remodeling is the loss of elastic
ﬁbers in the tunica intima and tunica adventitia. It has
been suggested that trophoblasts and VSMCs release
MMP-12 in a cooperative manner to degrade elastin.22
These events transform the arteries from narrow, pulsatile and high resistance tubes to wide, non-pulsatile
and low resistance vessels that allow steady ﬂow of
maternal arterial blood to the placenta for fetal nourishment. A failure of or a compromised remodeling of
the arteries is frequently associated with IUGR in the
fetus and or preeclampsia (PE) in the mother (Fig. 2).
Patho-biology of preeclampsia
PE is a serious maternal syndrome of placental origin
affecting 3–5% of pregnancies, associated with signiﬁcant
maternal as well as neonatal morbidity resulting from premature child birth. Clinical signs appear as unexplained
hypertension and proteinuria as early as at 20 weeks of
gestation in an otherwise normotensive mother. The disease is typically divided into 2 phases, the placental phase
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Figure 2. A schematic comparison of the structures of human
placentas in normal and preeclamptic pregnancy, showing poor
uterine spiral arterial remodeling in PE. Poor EVT invasion of the
spiral arteries is believed to compromise the arterial remodeling.
This causes reduced ﬂow of maternal arterial blood to the placental sinusoids resulting in hypo-perfused placenta that may result
in IUGR in the fetus and PE in the mother. (Adapted and modiﬁed
from Wang A, Rana S, Karumanchi AS. Preeclampsia: The Role of
Angiogenic Factors in Its Pathogenesis. Physiology. 2009 June; 24
(3):147–158.).

characterized by compromised trophoblast invasion and
uterine arterial remodeling, and the maternal phase characterized by wide-spread maternal endothelial damage
and dysfunction, possibly resulting from a variety of toxic
products released from a hypo-perfused, hypoxic placenta.23,24 These products may include lipid peroxidases,
syncytiotrophoblast microvillous fragments, and inﬂammatory chemokines.23-25 The placental origin of the disease is supported by the fact that a complete cure lies in
the delivery of the placenta. Many studies indicate that a
deﬁciency of trophoblast migration/invasion promoting
factors or an increase in trophoblast migration/invasion
restraining factors in situ may be associated with this disease (reviewed in refs. 13, 23, 24). Some of them may
appear as blood biomarkers.
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trophoblast growth, migration and invasion in a positive
or negative manner to maintain a healthy utero-placental
homeostasis. These molecules include growth factors,
inﬂammatory cytokines, growth factor binding proteins
and proteoglycans and lipid derivatives produced by the
trophoblast (autocrine) or the decidua including decidual
leukocytes and immune cells (paracrine). Success in
propagating pure human ﬁrst trimester EVT cells in
vitro, having the phenotype of EVT cells in situ,26-28 has
helped to identify some of the receptor-ligand interactions and signaling pathways regulating their proliferative, invasive and migratory functions and their
alteration in PE.13,29-31 While the mechanisms for EVT
cell invasion are shared with cancer cells,32-41 in contrast
to cancer cells, EVT cell proliferation, migration and
invasiveness are stringently regulated in situ.1,2,7,13,41-45
To explore this regulation, a number of in vitro models
have been utilised: (a) when villus cytotrophoblast cells
are placed on matrigel, a subset (progenitor cells) differentiated along the invasive pathway,46 a process stimulated by EGF47 and IL-1b.48 When grown on plastic,
they differentiated into syncytiotrophoblast,49 but
become enriched for EVT cells when plated on laminin.50 (b) Chorionic villus explants when plated on
matrigel.51 led to EVT cell sprouting that was stimulated
with decidua derived activin.52 and uterine NK cell
derived IFN-g.53 (c) Our laboratory developed a method
of propagating pure ﬁrst trimester EVT cells from villus
explants,26-28 duplicated by others.21 They express all the
in situ markers of EVT: cytokeratin 7, HLA class 1
framework antigen, uPA-R, IGF-II mRNA and protein,
and integrin chains a1, a5, av,b1 and vitronectin receptor
avb3/b5 but not a6 or b4,28 and HLA-G when grown on
laminin or matrigel.54 They senesce after 5–15 passages.28 Subsequently, we produced an immortalised
EVT cell line HTR-8/SVneo, by SV40-Tag transfection
of a short-lived line HTR-8.55 This cell line has fully
retained the normal EVT cell phenotype including
expression of cell surface HLA-G. Since in vitro derived
cell lines can only serve as in vitro models for studies of
molecular pathways, not otherwise identiﬁable, they
need to be veriﬁed with primary isolates of trophoblast
at least in limited experiments, whenever feasible. Utilizing HTR-8 and HTR-8/SVneo cells, and villus explant
cultures on matrigel, our laboratory and others have
established that locally-produced molecules which regulate EVT cell functions can be broadly placed into 3
functional groups.

Factors regulating EVT cell proliferation,
migration and invasiveness

Factors stimulating EVT proliferation

A large number of molecules produced at the fetalmaternal interface were shown to exquisitely regulate

(A) Members of the EGF family EGF,56 TGF-a,56,57 and
amphiregulin,58 produced in situ stimulated EVT cell
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growth. EGF also promoted differentiation of cytotrophoblast stem cells along the invasive pathway.48
(B) CSF-1 produced by pregnant endometrial glands,5962
stimulated EVT cell proliferation but not invasiveness.63 (C) Decidua-derived VEGF-A,64 and PLGF,65
also stimulated EVT cell proliferation, only in the
absence of heparin binding domains. EVT cells expressed
receptors for both VEGF-A (Flt-1, KDR) and PLGF
(Flt-1).64,65
Factors stimulating EVT migration and invasiveness
Certain trophoblast-derived molecules including IGF-II
and uPA, decidua-derived molecules including IGFBP-1,
endothelin-1, PGE2, and chemokines CX3CL1, CCL4,
CCL14 and villus mesenchymal cell derived molecules
such as HGF were shown to stimulate EVT cell migration and invasiveness.
Roles of IGF-II and IGFBP1
In situ hybridization revealed that EVT cells invading the
decidua expressed IGF-II mRNA, whereas decidual cells
in the proximity of invading EVT cells expressed IGFBP1 mRNA, suggesting a molecular cross talk at the fetalmaternal interface.66 To our surprise both molecules
independently stimulated EVT cell migration and invasiveness. IGF-II actions were mediated by binding IGFIIR, involving inhibitory G proteins and activation of
ERK1/2.67 Decidua-derived IGFBP-1 also stimulated
EVT cell migration independent of IGF-I or IGF-II binding. This was mediated by binding of the Arg-Gly-Asp
(RGD) domain of IGFBP-1 to a5b1 integrin on the EVT
cell surface, followed by activation of FAK and MAPK.68
Patho-physiological signiﬁcance of these ﬁndings was
demonstrated by low IGFBP-1 levels in early gestation
sera of women destined to develop PE.69-72 and low
IGFBP-1 mRNA expression by the decidua in PE.73
Increased IGFBP-1 levels in maternal blood reported
during overt PE.74 appear to be non-decidual in origin.73
Migration stimulation by uPA
EVT cells produced uPA,75 expressed high afﬁnity uPA
receptors (uPAR).76 and showed a polarized distribution
of uPAR-bound uPA on cell surface at the invasion front
in situ.77 While EVT cells used the catalytic domain of
uPA for matrix degradation,1,7 the binding of its aminoterminal to the EVT cell surface uPAR stimulated EVT
cell migration resulting from an elevation of [Ca2C]i, and
activation of PLC, PI3K and MAPK.78 These ﬁndings
may explain the reasons for the observed uPA/uPAR
imbalance in sera of PE mothers.79

Migration stimulation by endothelin (ET)-1 and PGE2
ET1is produced by vascular endothelial cells within the
placenta and the decidua. ET1 action on EVT cells was
shown to follow PLC-dependent elevation of [Ca2C]i and
activation of MAPK.80 PGE2, a major decidual product,
was shown to stimulate EVT cell migration.81-83 by binding to PGE receptors, in particular EP1 and EP4. EP1mediated migratory responses resulted from an increase
in [Ca2C]i because of release from intracellular storage
sites, and an activation of the calpain family of [Ca2C]i
dependent proteases, required for cell detachment from
the substratum.81 Migratory responses resulting from
EP1 or EP4 activity were dependent on RhoA-ROCK
pathway, in which ROCK played an obligatory role,
whereas RhoA action could be substituted by MAPK.
However, RAC1 and CDC42 played an essential role in
PGE2 or EP1/EP4 mediated migratory responses.82,83
These ﬁndings are relevant to intervention of PE, in
which trophoblast hypo-invasiveness and increased
peripheral vascular resistance in the pregnant mother
has been ascribed to decreased levels or responses to
PGE2.
Migration stimulation by chemokines and HGF
Human decidual cells and endometrial gland cells produce a plethora of chemokines including CX3CL1, CCL4
and CCL14. They were shown to promote human trophoblast migration by binding to chemokine receptors
on EVT cells.84 Chorionic villus mesenchymal cells
include a multipotent subset of stromal cells which produce many soluble cytokines and growth factors including HGF.85 HGF exibited migration and invasion
stimulatory effects on EVT cells.85-87 HGF stimulated
EVT cell motility depended on both MAPK and PI3K
signaling pathways and iNOS expression.86 HGF ligation
of the c-Met receptor on EVT cells stimulated MMP-9
expression and elevation of cAMP leading to protein
kinase A (PKA)-dependent Rap1 and integrin b1 activation.85 These ﬁndings are consistent with the reports of
reduced HGF production by the PE placentas 87 and
reduced soluble Met (s-Met) in the blood of PE
mothers.88
Factors blocking EVT cell proliferation, migration
and invasiveness
All these EVT cell functions are controlled mostly in a
paracrine manner by at least 3 decidua-derived factors
TGFb, TNFa and DCN. TGFb is produced by the
syncytiotrophoblast and most abundantly by the
decidua.27,29 This molecule exerts anti-proliferative,27
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anti-migratory.68,89 and anti-invasive.7,35,90 actions on
EVT cells. The anti-migratory function resulted from an
up-regulation of integrins, making the cells more adhesive to the ECM.89 The anti-invasive action was a combined result of reduced migration, a reduction of matrixdegrading ability because of down-regulation of
uPA.35,91 and upregulation of protease inhibitors TIMP1.35 and PAI-1.91 EVT cells expressed all the TGFb
receptors (RI, II, III), downstream signaling molecules
SMAD proteins (receptor associated smads 2, 3, co-smad
4, and inhibitory smads 6, 7) and responded to TGFb by
phosphorylation and nuclear translocation of smad 392
and smad-dependent up-regulation of PAI-193 and
TIMP-1.94 Trophoblast cells also express a TGFb coreceptor endoglin which binds TGFb-1 and b3 but not
b2.95,96 A stimulation of EVT cell sprouting in villus
explant cultures noted after blocking endoglin.96 is consistent with proliferation, migration and invasion-blocking roles of endogenous TGFb.31 A failure of
downregulation of TGFb-3 in villi was postulated as a
precursor of preeclampsia.97 Nodal, another member of
the TGFb superfamily inhibits EVT migration by activation of ALK7, and nodal/ALK7 overexpression is implicated in PE.98 We discovered that choriocarcinoma cells
are resistant to anti-proliferative and anti-invasive
actions of TGFb,99 primarily due to loss of smad3
expression.92-94 TNFa, a product of decidual macrophages was shown to inhibit EVT cell migration by upregulating PAI-1.100 We observed that a TGFb-binding
and inactivating proteoglycan DCN is co-localized with
TGFb in the decidual ECM, suggesting that DCN may
serve as a reservoir for TGFb in its inactive form,29 until
trophoblast-derived protease cascade at the invasion
front breaks DCN-TGFb complex and activates TGFb to
prevent over-invasion. However, to our surprise, DCN
on its own was found to block EVT cell proliferation,
migration and invasiveness, independent of TGFb. An
upregulation of p21 (a CDK inhibitor) explained, in part,
the anti-proliferative effects. Again, choriocarcinoma
cells proved to be resistant to these DCN actions.30

Structural basis of DCN functions
DCN is a small leucine-rich proteoglycan (SLRP) produced in a variety of connective tissues, such as the
dermis, cartilages, the decidua,29,30 and mesenchymal
cells of the chorionic villi.29,101 A diagram of mature
DCN structure derived from numerous studies102-104
is presented in Figure 3. It consists of a 40 kDa core
protein, harbouring 10 leucine-rich repeats (LRR),
covalently linked with a tissue-speciﬁc glycosaminoglycan (GAG) chain (chondroitin or dermatan sulfate)
at its N-terminus of domain II. The protein is
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Figure 3. A schematic diagram of the structure of human
decorin. It contains backbone of a 40kDa core protein containing
4 domains. Domain-I contains a propeptide and a signal peptide
(in green) which are cleaved in the matured protein. Domain-II is
covalently linked with a GAG chain at its N-terminus. Domain-III
contains 10 Leucine Rich Repeats (LRR) and N-linked Glycan sidechains (in orange). Domain -IV contains cysteine residues and
forms a large loop.The TGFb binding sites are located in LRR4
and LRR5. The VEGFR-2 binding site is located within LRR5. The
binding site for myostatin is currently undetermined.

encoded by chromosome 12q22 in the human. The
mature protein is highly conserved across various species and responsible for many of the biological functions. It regulates matrix assembly, including collagen
ﬁbrillogenesis because of its ability to bind collagen
type1. DCN null mice survive to adulthood, but show
poor fertility and skin fragility due to disruption of
collagen ﬁbrils in the dermis.105 Mutation of DCN
gene has been associated with a rare autosomal dominant form of corneal dystrophy called “Congenital
stromal corneal dystrophy (CSCD)," also named as
“Witschel dystrophy.”106 Mice genetically deﬁcient in
both DCN and biglycan genes undergo preterm labor
and expulsion of the fetus owing to premature rupture of the fetal membranes.107 Because of its TGFb
binding ability at LRR4 and 5, DCN can store TGFb
in the ECM.103 It can inactivate mature TGFb in
some circumstances108 but not others,109 apparently
by interfering with TGFb-binding to types I and III
TGFbR. Whether this occurs universally in vivo is
unclear, since the inactivation improves in vitro after
removal of the GAG chains.110 DCN can also bind myostatin, another member of the TGFb superfamily and a
myogenic inhibitory protein.111 This binding has been
shown to support myogenesis by inhibition of myostatin.
For example, DCN immobilized on ECM in vitro
sequesters myostatin into the ECM, preventing its inhibitory action on myoblast proliferation. Furthermore,
ectopically introduced DCN into myoblasts promotes
their proliferation and differentiation by inactivating
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TKR mediated DCN actions of EVT cells and
endothelial cells
We investigated whether EGFR, IGF-IR and VEGFR-2
played a role in negative regulatory actions of DCN in
EVT cells.31 We noted that these TKRs are promptly
phosphorylated by DCN similar to their natural ligands,
and these events can be blocked with respective tyrosine
kinase inhibitors. We found that DCN inhibits EVT cell
outgrowth in situ from intact ﬁrst trimester chorionic villous explants on matrigel. Using our EVT cell line HTR8/SVneo, we further showed that anti-proliferative action
of DCN is mediated primarily by EGFR and VEGFR-2,
and anti-migratory action primarily by IGF-IR. Furthermore, VEGF-A mediated migration of EVT cells was
blocked with DCN in a VEGFR-2 dependent manner.124
Figure 4. A schematic diagram of the VEGFR-2 binding site in a
12 aa span of LRR5 in decorin protein core. The VEGF-A and
decorin binding sites of VEGFR-2 are overlapping. (Reproduced
with permission from Khan GA, Girish GV, Lala N, Di Guglielmo
GM, Lala PK. Decorin is a novel VEGFR-2-binding antagonist for
the human extravillous trophoblast. Mol Endocrinol. 2011 Aug;
25(8):1431–43.).

endogenous myostatin.112 DCN can modulate cell adhesion by binding with ECM molecules ﬁbronectin113,114 or
thrombospondin.115 However, as elaborated below, many
DCN functions are also receptor-mediated.
DCN acts as an antagonistic ligand to numerous
tyrosine kinase receptors
EGFR was the ﬁrst DCN receptor identiﬁed by the Iozzo
group116-120 having a lower afﬁnity than EGF. DCN-binding led to a transient phosphorylation of EGFR kinase,
followed by a reduction of the receptor number, attributed to accelerated receptor endocytosis by the caveolar
pathway. DCN binding was mapped within a narrow
region of the ligand binding domain 2 of the EGFR, partially overlapping with the EGF-binding domain.119 A
second DCN receptor IGF-IR was soon identiﬁed on
endothelial cells that could bind DCN with an afﬁnity
comparable to IGF-1, showing DCN induced receptor
phosphorylation, followed by receptor down-regulation.121 However DCN could also bind IGF-I, compounding the biological effects of DCN on endothelial cells in
the presence of IGF-I in the micro-environment.121 Subsequently DCN was shown to be an antagonistic ligand
for Met, the receptor for HGF.122 Since DCN core protein
and its 26-amino acid residue LRR5 were shown to inhibit
VEGF-induced angiogenesis in endothelial cells in
vitro,123 we suspected that the anti-angiogenic action of
DCN may have resulted from DCN binding to VEGFR-2.

Molecular localization of VEGFR-2 binding on DCN
protein
Far-Western blotting and co-immunoprecipitation studies
revealed that DCN binds both native (EVT or endothelial
cell expressed) and recombinant VEGFR-2 and that this
binding is abrogated with a VEGFR-2 blocking antibody,
indicating an overlap between the ligand-binding and the
DCN-binding domains of VEGFR-2125 I-labeled VEGF-E
(a virus-derived VEGFR-2 speciﬁc ligand) bound to EVT
with a Kd of 566 pM, and DCN displaced this binding
with a Ki of 3.93–5.78 nM, indicating a 7 to 10-fold lower
afﬁnity of DCN for VEGFR-2. DCN peptide fragments
derived from its LRR- 5 domain that blocked DCNVEGFR-2 interactions or VEGF-E binding in EVT cells
also blocked VEGF-A and VEGF-E-induced EVT cell
proliferation and migration, indicative of functional
VEGFR-2-binding sites of DCN in a 12 AA span of LRR5
(Fig. 4). This binding inhibited VEGF-induced EVT
migration by interfering with ERK1/2 activation. Subsequently we explored the mechanisms for VEGFR-2
dependent DCN antagonism of migration and endovascular differentiation of EVT cells.125 We found that DCN
inhibited VEGF-induced EVT cell migration and endothelial-like tube formation (an in vitro surrogate of endovascular phenotype). VEGF activated p38 MAPK, MEK3/
6, and ERK1/2 in EVT cells, and the activation of these
pathways was blocked by DCN. Employing selective
MAPK inhibitors, we showed that both p38 MAPK and
ERK pathways contributed independently to VEGFinduced EVT migration and tube formation. VEGF-mediated up-regulation of endothelial markers VE-cadherin
and b-catenin in EVT as well as endothelial cells was
blocked by DCN and MAPK inhibitors. These results
revealed that DCN inhibits VEGF induced EVT
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migration and endovascular differentiation by interfering
with p38 MAPK and ERK1/2 pathways in parallel.125
Mechanisms of DCN actions on the trophoblast
Decidua-derived DCN appears to be a powerful negative
regulator of trophoblast migration and invasion independent of TGFb binding; this was primarily due its
binding and antagonizing several TKRs including EGFR,
IGF-IR, Met, and VEGFR-2 which promote these functions when stimulated by their natural ligands. The
underlying mechanisms are most likely similar to those
reported with other cell types. In the case of EGFR, DCN
binding is followed by a rapid receptor endocytosis and
degradation by the caveolar pathway and a retardation
of the receptor recycling.120 A rapid receptor internalization and receptor shedding were noted after DCN binding to Met, followed by downregulation of b-catenin and
Myc.122 DCN antagonized IGF-IR functions in tumor
cells by interfering with IGF-IR activity and attenuating
downstream signaling, but no change in receptor endocytosis.126 In the case of VEGFR-2 binding to DCN, we
found no evidence of accelerated receptor endocytosis in
comparison to VEGF binding on EVT cells (Lala PK and
Girish GV, unpublished data). VEGFR-2 binding compromised trophoblast migration and endovascular differentiation by interfering with p38 MAPK and ERK1/2
pathways in parallel.125 It is highly likely that other
TKRs with DCN binding ability will be identiﬁed in the
future on cells including trophoblast.
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explained on the basis of VEGFR-2 binding of these molecules demonstrated by us.124 (iv) DCN mediated down
regulation of VEGF production by tumor cells was
shown as another mechanism for suppression of tumorinduced angiogenesis in vitro and in vivo. This was demonstrated by addition of exogenous DCN to tumor cells
or ectopic DCN expression in tumor cells.130 (v) DCN
can also act on VSMC by binding to PDGF, a growth
promoter of VSMC. DCN binding to PDGF inhibited
PDGF-stimulated PDGFR phosphorylation and proliferation of VSMC, required for angiogenesis.131 Pro-angiogenic actions: DCN null mice exhibited reduced corneal
angiogenesis in response to injury, suggesting a proangiogenic role of DCN.127 However, this may possibly
be explained by upregulation of pro-angiogenic biglycans.132 or activation of endogenous TGFb which can
have indirect angiogenic functions.133 DCN null mice
were shown to up-regulate biglycans107 which were
reported to have angiogenic ability.132 Finally, targeted
DCN gene therapy blocked angiogenesis in mouse cornea,134 reinforcing its anti-angiogenic role. Other proangiogenic actions of DCN can possibly be explained in
the context of DCN-ECM interactions, favoring the
assembly of a pro-angiogenic matrix.127,135 For example,
endothelial tube formation was stimulated in DCN overexpressing cells placed in a 3D matrix which allowed
DCN binding to both IGF-IR and IGF-I.121 It is also possible that the nature of microvasculature may dictate
DCN action. For example, ectopic DCN over-expression
in mouse cerebral endothelial cells upregulated VEGF-A
to promote angiogenesis.136

Role of DCN in angiogenesis
While most studies have established that DCN blocks
angiogenesis, some studies suggested a pro-angiogenic
role. This difference is ascribed to differences in the cellular and molecular environment in DCN action, elegantly reviewed by Jarvelainen et al.127 Anti-angiogenic
actions: Many studies including ours have identiﬁed
DCN as a potent anti-angiogenic molecule due to its
actions on vascular endothelial cells, mediated by multiple mechanisms: (i) In vitro studies with vascular endothelial cells revealed that DCN binding to the ECM
molecule thrombospondin-1 enhances anti-angiogenic
role of this molecule.128 (ii) DCN binding to IGF-IR
blocked angiogenesis in tumor cells,126 in contrast to
increased motility reported for endothelial cells grown
on type 1 collagen matrix.129 (iii) VEGFR-2, the most
potent pro-angiogenic receptor on endothelial cells,
antagonizes VEGF-mediated migration and tube formation both by the trophoblast and endothelial cells.124,125
Inhibition of VEGF-induced angiogenesis by DCN or
certain DCN peptides reported earlier123 can be

Role of DCN in tumor progression
Interestingly, many of the DCN actions in restraining
placental invasion of the pregnant uterus and its vasculature are also applicable to tumor progression. Currently
there is a substantial amount of literature suggesting that
DCN has tumoristatic functions in certain cancers
because of its dual roles: limiting angiogenesis and antagonising TKRs having oncogenic roles because of their
mutational activation. Additional mechanisms have also
been found. It has been suggested DCN is a natural
tumor-suppressor molecule that can be harnessed for
therapy. Indeed, SLRPs including DCN have been shown
to play an important role in health and disease including
cancer.137 These molecules produced by stromal cells in
ECM within the tumor micro-environment are believed
to be important contributors in controlling tumor
growth.137,138 In support, the relative level of DCN
expression in soft tissue tumors has been correlated with
prognosis.139 Some studies examined the effects of either
ectopic introduction of DCN gene, or a deletion of DCN
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gene. For example, Grant et al.130 demonstrated reduced
angiogenic abilities of DCN transfected ﬁbrosarcoma,
osteosarcoma and carcinoma cell lines tested in vitro and
in vivo. DCN transfection of breast carcinoma cells was
shown to antagonise an elaborate angiogenic network.
There was concurrent inhibition of Met, HIF-1a and
induction of angiostatic molecules thrombospondin-1
and TIMP-3.140 Deletion of DCN gene promoted colorectal carcinogenesis in a mouse model.141 Using a DCN
knockout mouse model, these authors demonstrated that
colorectal carcinogenesis resulting from DCN knockdown
was associated with epithelial mesenchymal transition
(EMT), as marked by down-regulation of E-cadherin and
up-regulation of b-catenin.142 Goldoni et al.143 demonstrated anti-metastatic role of exogenous DCN treatment
in experimental breast cancer. They compared the effects
of DCN alone or in combination with an ErbB2 kinase
inhibitor AG879 on the growth of an ErbB2-over-expressing mammary carcinoma cell line. DCN was shown to
inhibit ErbB2 kinase in tumor cells. When DCN and
AG879 were used in combination, the inhibitory effects
were synergistic or additive on tumor growth in vitro.
While the combination therapy did not improve antitumor effects of DCN on primary tumor growth in vivo,
DCN signiﬁcantly reduced lung metastasis. Similarly
DCN and carboplatin were shown to have synergistic
growth-inhibitory effects on ovarian cancer cells.144 However, caution has been raised against DCN therapy in
human pancreatic cancer.145 In pancreatic cancer tissues
DCN overexpression was noted in stromal satellite cells
possibly as a protective defense mechanism. While DCN
alone had cytostatic effects on several pancreatic cancer
cell lines in vitro, it attenuated cytostatic effects of carboplatin or gemcitabine in some cell lines. It is likely that
DCN will be useful in combination therapies in tumors
with low DCN expression in situ. Furthermore, genetic
mutations may lead to DCN resistance in certain cancers.
For example, in contrast to the migration and invasion
restraining roles of decidua-produced DCN as well as
TGFb on the normal human trophoblast cells, as detailed
earlier, we found that human choriocarcinoma cells are
resistant to both molecules,30,92-94,99 explaining their
emancipation from decidua-mediated controls.

Possible role of DCN over-expression in the
decidua in pathogenesis of PE
DCN mediated dual impediment of endovascular differentiation of the EVT and angiogenesis,124,125 hallmarks
of PE, may imply that DCN overexpression at the fetalmaternal interface may contribute to the pathogenesis of
PE. We tested this contention by quantitating DCN
expression in placentas from 16 healthy and 16 PE

pregnancies at comparable gestational ages using 2
approaches.146 DCN mRNA expression at the tissue level
was quantiﬁed with real time qPCR in chorionic villus
tissues. DCN mRNA at the cellular level was measured
both in chorionic villi and decidua basalis employing in
situ hybridization with35S labeled antisense cRNA probe.
Hybridization with sense cRNA probe served as controls.
Using both approaches we found that DCN expression
by chorionic villus mesenchymal cells was unaltered in
PE. In contrast, DCN mRNA expression by decidual cells
in the basal plate (where EVT cells invade) was profoundly up-regulated in PE placentas, as compared to
healthy placentas of equivalent gestational ages. Immunocytochemical localization of DCN in the same tissues
conﬁrmed these ﬁndings at the protein level. We suggest
that over-expression of DCN in the basal decidua contributes to the pathogenesis of PE because of a dual
action of DCN on the trophoblast and endothelial cells.
In the former DCN causes a hypo-invasive phenotype
and poor endovascular differentiation. Anti-angiogenic
action of DCN on endothelial cells in combination with
poor endovascular differentiation of the trophoblast contribute to poor uterine arterial remodeling. In addition,
we discovered that exposure to exogenous DCN or
ectopic overexpression of DCN in EVT cells signiﬁcantly
upregulated the expression of sFlt-1. This anti-angiogenic molecule produced by the trophoblast in PE placentas is recognized as a blood biomarker in PE
mothers.147 All these events are patho-biological hall
marks of placentas associated with PE. We suggest that
DCN in the maternal blood is another potential biomarker in PE. This suggestion has recently been validated by longitudinal studies of maternal plasma
samples in pregnant subjects during the second trimester
(Siddiqui M et al. submitted for publication).

Gaps in knowledge and future directions
DCN is a multifunctional molecule, the functions mediated by a variety of binding events that regulate cell
adhesion, migration and invasion. DCN can inactivate
TGFb under certain conditions, but whether this happens in situ in the decidua where they are co-localized,
remains to be explored. DCN binds numerous TKRs
which have been identiﬁed; it may possibly bind to other
TKRs that remain to be identiﬁed. It is highly likely that
some of the DCN actions on the trophoblast are receptor-independent, mediated by binding to ECM molecules
that remain to be identiﬁed. We have preliminary evidence that DCN binding to EVT cells compromises
many other functional events such as intercellular communications that remain to be fully characterized at the
molecular level. The role of DCN on VSMC and
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trophoblast-VSMC interactions remain an area of investigation in the context of uterine arterial remodeling.
Very little information is available as to whether DCN
acts as a protective molecule in trophoblastic tumorigenesis or metastasis to the placenta from pregnancy-associated cancers in maternal organs including the breast.
Recently Borbely et al.148 reported immunohistochemical
localization of DCN protein in trophoblast cells of invasive pregnancies including placenta acreta accreta, invasive moles and choriocarcinomas, the signiﬁcance of
which remains unknown. One possibility is that these
hyper-invasive placental pathologies involve epithelialmesenchymal transition of the trophoblast, allowing cells
to make this mesenchymal molecule. In situ hybridization is needed to conﬁrm the cellular source of DCN in
these pathologies.
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